Ranbaxy Laboratories Limited

COMMERCIAL PRESENTATION

-Rohit Shrivastava
MSc Drug Development with Bio-business
University of Aberdeen, U K
Introduction
Ranbaxy Lab. Ltd is India’s largest
Pharmaceutical company was established in
1961. It is a research based International
company with its headquarters at Gurgaon,
India.
Its CEO & Managing Director is Mr. Atul Sobti.
Global Presence
• It has been ranked 8thth among the top global generic
Pharmaceutical companies.
• It has consumers in over 125 countries and a total revenue of
$ 1.7 Bn.
• It is present in 49 countries and has manufacturing units in
11 countries.
• It has a strong workforce of more than 12,000 employees.
Sector

Ranbaxy specializes in oral delivery systems, peptides , anti-infectives, Oncology

(through Zenotech ). Active Pharmaceutical ingredients, Dosage forms.

●
Current research is going on taste masking, gels, chewable tablets, effervescent.

Ranbaxy acquired in-licenses from Ochoa Lab. Ltd for its entire range of
dermatological and lifestyle products.

●
In-licensed asthetic dermatology products from Darier (Mexico) & Medy tox ( S.
Korea).
Alliance and Acquisitions
• Has active alliances with numerous companies all over the world.

• Ciprofloxacin oral once daily formulation developed by Ranbaxy was out licensed to
Bayer AG, Germany to exclusively market the drug for $10Mn and royalties.

• Alliance with Zenotech increased the foothold in Biopharmaceuticals.

• Ranbaxy works in alliance with GsK and Merck in the area of New Drug Discovery and
Clinical Development.

• Ranbaxy out-licensed its statin molecule to PPD Inc. USA.

• Acquired generic business of companies in Germany (Bayer), Spain (EFARMES ) &

(Mundogen), S. Africa (Be Tabs), Italy and Spain (GsK) , Romania (Therapia), Italy (Allen),
Belgium (Ethimed), USA (Derma brands & Auto-injector Technologies), India (Orchid,
Zenotech, Krebs, Jupiter & Cardinal Drugs) .
Business Model
• Ranbaxy continues to evaluate acquisition opportunities
in India, emerging & developed market to accentuate its
business & competitiveness.

Strength Weakness
- Low manufacturing - Low investment in
cost innovative R&D
- Access to the pool of - Lack of strong links
highly trained scientist between industry and
- Presence in global as academia.
well as emerging - Low healthcare
market budget

Threats Opportunities
- Potential to develop India
- Exports hampered by as a center for International
procedural hurdles in clinical trials.
India and non-tarrif -Potential for drug discovery
hurdles abroad. and clinical development.
- Personalized medicine - In-licensing products from
MNC to market in domestic
- Fake drugs lead to loss as well as International
in sales market.
The Pipeline
• Ranbaxy’s NDDR program is focused
on infectious disease, metabolic
disease, respiratory disease and Oncology.

• 8 NCE’s in pre clincal development, Phase I & II (2 molecules in collaboration with

GsK)

• Potential anti-malarial Arterolane is in Phase III & Clafrinast for respiratory

inflammation is in Phase II clinical trials.

• Dyslipidemia RBx 10558 (hyperlipidemia)is in developmental stage. DPP-IV inhibitor

for Type 2 Diabetes. Phosphodiasterase inhibitor for asthama, novel antibacterials
for community acquired respiratory infection are in developmental stage.

• Ranbaxy has filed 5 IND applications in India. 1 IND in UK for anti-malarial drug RBx
11160.

• Ranbaxy has 62 product’s ANDA and 16 FTF’s pending for approval worth $50 Billion
and had a total of 310 approvals during 2009.
Consumer Healthcare

• Ranbaxy Global Consumer Healthcare (RGCH) was

initiated in 2001.
• RGCH has unique business communication
platform “The Rainbow Coalition” which involves
doctors at on end and consumers at the other end.
• In 2006, RGCH business generated sales of US$ 19
Mn with a growth of 19%.
• Over The Counter products-
– Revital (mineral & vitamin supplements)
– Chericof (cough syrup)
– Eat ease (Appetite stimulant)
Financing & Investment
• Cash flow from financial institutions, Foreign institutional investors, corporate bodies &
investment in subsidiary companies.

• Due upfront payment of $100 Mn and roylaties worldwide from GsK for anti-infectives
developed by Ranbaxy.

• Upfront and royalties of undisclosed amount from Merck for anti-fungal and anti-
bacterial development and clinical trials.

• Company is registered in Bombay stock exchange and in National stock exchange . Gold
depository shares are listed on Luxembourg stock exchange.

• In Q3 FY 2009 report, Ranbaxy has shown net sales of US$ 356 Mn & 13 % growth and
a profit of US$ 24 Mn.

• Ranbaxy has entered into strategic alliance with Daiichi Sankyo with Daiichi having
63.9% of stake in Ranbaxy. This has strengthened balance sheet, de-risked its business,
widened the market and Ranbaxy will have access to low cost R&D and manufacturing
facilities.
Future Aspirations
• Based on prowess in New Drug Development
system and NCE Research and one third to one
fifth cost of developing a new drug in India
Ranbaxy is focusing on novel therapeutic
agents.
• To develop strong presence in developed
markets.
• Aspires to be in top 5 global companies.
Summary
• Presence across all key developed & emerging
markets.
• Strong distribution network.
• Cost efficient India based Research &
Development and Manufacturing.
• Focus on NCE research
• 8 molecule in pipeline.
• 10-15 patents each year.
 THANK YOU

QUESTIONS???